logo
logo

Good Therapeutics Announces Acquisition Of Conditionally Active Pd-1-Regulated Il-2 Program By Roche

Good Therapeutics Announces Acquisition Of Conditionally Active Pd-1-Regulated Il-2 Program By Roche

09/07/22, 11:03 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgseattle
Industry
therapeutics
biotechnology
Good Therapeutics, a privately held company, today announced it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics.

Company Info

Company
Good Therapeutics, Inc.
Location
eastlake avenue east
Seattle, Washington, United States
Company info
Good Therapeutics is a biopharmaceutical company focused on the generation of a new class of drugs that offer potent activity only where it is needed. The company’s regulated, context-dependent molecules combine an antibody sensor directed against a specific marker and a therapeutic component active only when the sensor has bound its target. The therapeutic component can be regulated by any molecule that an antibody can bind, including native proteins, modified proteins, and metabolites. Good Therapeutics’ technology is applicable to a wide range of areas including cancer, autoimmune diseases, metabolic disease, and pain management. A privately held company founded in 2016 and based in Seattle, Washington, Good Therapeutics, Inc. is backed by a group of leading venture investors including Codon Capital, RiverVest Venture Partners, 3x5 Partners, Roche Venture Fund, and Digitalis Ventures.

Related People